The Claim

Implemented an additional 10% tariff on imports from China in order to stem the flow of illegal aliens and fentanyl trafficked into our country.

The Claim, Unpacked

What is literally being asserted?

Two factual components: (1) the administration imposed an additional 10% tariff on Chinese imports, and (2) the purpose was to stem the flow of illegal aliens and fentanyl from China into the United States.

What is being implied but not asserted?

That a tariff on consumer goods is an effective tool for reducing illicit drug trafficking and unauthorized immigration. That China is a significant source of “fentanyl trafficked into our country” — when China primarily exports precursor chemicals, not finished fentanyl. That Chinese illegal aliens represent a significant immigration problem comparable to southern border crossings. That the tariff achieved its stated purpose. That the tariff remained in effect and was legally authorized.

What is conspicuously absent?

Any acknowledgment that the tariff was later raised to 20%, then reduced back to 10%, then struck down by the Supreme Court as exceeding presidential authority under IEEPA. Any mention that China exports fentanyl precursor chemicals, not finished fentanyl — the claim says “fentanyl trafficked into our country” but China’s role is upstream in the supply chain, with Mexican cartels producing the finished drug. Any disclosure that the tariff was paid by American importers and consumers, not by China. Any explanation of the mechanism by which a tariff on consumer goods (electronics, clothing, toys) would reduce illicit chemical shipments or unauthorized immigration. Any mention of the expert consensus — spanning Brookings, WOLA, The Lancet, AEI, and STAT News — that tariffs are ineffective against fentanyl. Any acknowledgment that China’s precursor chemical regulations were initiated under Biden-era diplomacy (the November 2023 Biden-Xi summit). Any context about the total tariff burden on Chinese goods (Section 301 tariffs of 7.5-25% were already in place, making the effective rate on many goods 35%+).

Evidence Assessment

Established Facts

The 10% tariff was imposed — this is factually true. On February 4, 2025, President Trump signed Executive Order 14195, imposing a 10% additional ad valorem tariff on all imports from the People’s Republic of China under the International Emergency Economic Powers Act (IEEPA). The tariff took effect immediately. The executive order cited “the extraordinary threat posed by illegal aliens and drugs, including deadly fentanyl” and specifically stated that “Chinese officials have failed to take the actions necessary to stem the flow of precursor chemicals to known criminal cartels.” The claim accurately describes a real policy action. [^047-a1]

The tariff was subsequently raised, reduced, and ultimately struck down. On March 4, 2025, the IEEPA fentanyl tariff on China was doubled from 10% to 20%. On November 10, 2025, following the Trump-Xi meeting in South Korea, it was reduced back to 10%, with the White House citing Chinese “commitments” to restrict precursor exports. On February 20, 2026, the Supreme Court ruled 6-3 in Learning Resources, Inc. v. Trump that IEEPA does not authorize the President to impose tariffs. All IEEPA tariffs — including the China fentanyl tariff — terminated on February 24, 2026. The tariff the claim describes no longer exists, having been found to exceed presidential authority. [^047-a2]

China is a precursor chemical supplier, not a direct fentanyl trafficker — the claim conflates the two. The Congressional Research Service, DEA, and State Department all document that China’s role shifted from exporting finished fentanyl (pre-2019) to exporting precursor chemicals after China banned fentanyl production in 2019. Chinese companies sell precursor chemicals (4-AP, 1-boc-4-AP, norfentanyl, and others) to Mexican cartels, which synthesize finished fentanyl in clandestine laboratories in Mexico. The finished drug is then smuggled into the U.S. primarily through legal ports of entry by U.S. citizens (86% at ports, 81% by citizens — see Item #7). The claim says China trafficks “fentanyl” into the U.S.; the accurate statement is that Chinese companies export precursor chemicals to Mexican cartels, which produce the fentanyl. This distinction matters because the policy implication is different: precursor regulation and law enforcement cooperation, not tariffs on iPhones, are the relevant tools. [^047-a3]

China’s precursor chemical enforcement remains “uneven and opaque” according to the U.S. government’s own assessment. The State Department’s September 2025 Mandatory Congressional Report on China Narcotics found that “the PRC’s enforcement of its counternarcotics regulations remains uneven and opaque” and that China “has in many instances not acted against companies selling non-scheduled fentanyl and other precursor chemicals.” This assessment was published just two months before the administration reduced the fentanyl tariff citing Chinese “commitments,” and before the 365 Days list claimed the tariff’s purpose was achieved. [^047-a4]

Chinese migrant encounters at the southern border surged in FY2023-2024 but represent a small fraction of total encounters. CBP encountered approximately 37,000 Chinese nationals crossing illegally in FY2023 (up from 330 in FY2021, a roughly 11,000% increase) and was on track for approximately 60,000 in FY2024. This was a real and significant increase, driven largely by economic fallout from China’s zero-COVID policies. However, Chinese nationals represent a small percentage of total southern border encounters (which exceeded 2 million in FY2023). More importantly, there is no logical mechanism by which a tariff on Chinese imports would deter Chinese nationals from migrating — the tariff applies to goods, not people. [^047-a5]

Strong Inferences

A tariff on consumer goods has no logical mechanism to reduce illicit drug trafficking or unauthorized immigration. Fentanyl precursors move through illicit channels — clandestine chemical company sales, dark web marketplaces, money laundering networks. A tariff on legal imports (electronics, clothing, toys, machinery) does not affect these illicit supply chains. WOLA’s analysis identifies the structural impossibility: “Fentanyl is so potent and compact that the quantity needed to supply the entire U.S. market is fairly minimal, so the drug war theater of arrests and interdiction doesn’t mean traffickers aren’t supplying the market.” The entire U.S. fentanyl supply could fit in a few shipping containers, while legal U.S.-China trade exceeds $500 billion annually. Taxing the latter cannot affect the former. Similarly, a tariff on Chinese goods does not create a migration deterrent — people fleeing economic hardship or political repression are not deterred by the price of consumer electronics. [^047-a6]

Experts across the political spectrum agree tariffs are ineffective against fentanyl. The Lancet Regional Health — Americas published a peer-reviewed article finding tariff-based measures “ineffective” against fentanyl trafficking. Brookings’ Vanda Felbab-Brown warned that tariffs on China would “likely eviscerate Beijing’s cooperation” on precursor chemicals — the one area where cooperation was producing results. WOLA published “Tariffs Won’t Stop Fentanyl.” AEI (a conservative think tank) published “Two Charts Show Why a Trade War Over Fentanyl Doesn’t Make Sense.” STAT News called tariffs “manifestly ineffective.” A former member of the federal Commission to End the Fentanyl Crisis wrote in CNBC that “tariffs aren’t the way to do it.” This consensus spans left, center, and right; public health experts and drug policy researchers; economists and security analysts. No credible expert assessment has identified tariffs as an effective anti-fentanyl tool. [^047-a7]

The tariffs risked undermining the China precursor cooperation that was actually working. China’s August 2024 precursor chemical regulations — adding 4-AP, 1-boc-4-AP, and norfentanyl to controlled lists — were negotiated through Biden-era diplomacy, particularly the November 2023 Biden-Xi summit. Brookings warned that tariffs would “eviscerate Beijing’s cooperation,” resetting progress to the non-cooperation period of 2021-2023. China did impose retaliatory tariffs on U.S. agricultural products (10-15% on soybeans, pork, beef, seafood) and restricted rare earth mineral exports. While a November 2025 trade deal eventually moderated the trade war, the tariffs created months of economic damage and diplomatic strain that risked the very precursor cooperation experts identified as the most promising anti-fentanyl tool. [^047-a8]

The tariff was paid by American consumers, not China. The Yale Budget Lab calculated that the initial 10% tariff on China reduced average disposable income by 0.14%, with a regressive burden: low-income households (who spend more on Chinese-manufactured goods) bore disproportionate costs. The nonpartisan Tax Foundation estimated the combined tariff regime (Canada, Mexico, and China) amounted to an average tax increase of approximately $1,500 per U.S. household. When stacked on top of existing Section 301 tariffs (7.5-25%), the effective tariff rate on some Chinese goods exceeded 35%. Penn Wharton estimated cumulative IEEPA tariff collections reached approximately $164.7 billion by January 2026, with China accounting for 24% of monthly revenue. These costs were borne entirely by American importers and consumers, not by Chinese exporters. [^047-a9]

Informed Speculation

The claim’s placement in the “SECURING AMERICA’S BORDERS” section, alongside immigration enforcement items, frames a trade policy action as a border security measure. This framing serves multiple strategic purposes.

First, it wraps tariffs in the politically potent cause of fighting fentanyl and illegal immigration. Tariffs imposed “to protect American manufacturers” face political opposition from free-trade advocates, business groups, and consumers facing higher prices. Tariffs imposed “to stem fentanyl and illegal aliens” are far harder to oppose, because anyone questioning the tariff can be characterized as soft on drugs and borders.

Second, the claim leverages the public’s unfamiliarity with the fentanyl supply chain. Most Americans do not know that China exports precursor chemicals rather than finished fentanyl, or that Mexican cartels operate the synthesis labs, or that U.S. citizens smuggle the finished product through legal ports of entry. The claim’s language — “fentanyl trafficked into our country” — implies China ships fentanyl directly into America, which is not how the supply chain works.

Third, by listing the tariff as a border security “win,” the administration obscures that the tariff was primarily a trade instrument. The same executive order that cited fentanyl and immigration also served broader trade policy objectives — reshoring manufacturing, reducing the trade deficit, and providing leverage in U.S.-China economic negotiations. The fentanyl justification provided political cover for tariffs that experts said would not affect drug trafficking.

The November 2025 tariff reduction — from 20% back to 10% following the Trump-Xi trade deal — reveals the tariff’s true nature. If the tariff’s purpose were genuinely anti-fentanyl, its reduction would depend on evidence of reduced fentanyl precursor flows. Instead, the reduction was part of a broader trade deal involving soybean purchases and rare earth mineral access. The tariff’s stated purpose (fentanyl/immigration) and its actual use (trade negotiation leverage) diverge.

Structural Analysis

Stated vs. revealed preferences. The stated preference is reducing fentanyl trafficking and illegal immigration from China. The revealed preference is using fentanyl and immigration as justification for trade tariffs that serve broader economic objectives. Evidence: (a) the tariff was reduced not when precursor flows decreased, but when China agreed to trade concessions (soybeans, rare earths); (b) the tariff applied to all Chinese imports regardless of connection to fentanyl or immigration; (c) the executive order’s own language focused on “precursor chemicals” but the policy response was a consumer goods tariff, not precursor-specific sanctions.

The tool-mismatch problem. This is the structural core of the claim’s dishonesty. The government has tools that actually target fentanyl precursor suppliers: sanctions on specific companies (Treasury/OFAC), criminal indictments (DOJ), diplomatic pressure for enforcement cooperation, export control negotiations, and intelligence-sharing agreements. These are precise instruments that target the actual problem — Chinese chemical companies selling precursors to Mexican cartels. A tariff on all Chinese imports is a blunt instrument that taxes American consumers to buy goods they were already buying, with no connection to the illicit precursor trade. It is like imposing a toll on all roads in the state to reduce jaywalking on one specific street.

Cui bono. American consumers and importers pay the tariff. Chinese exporters may lose some market share. The U.S. Treasury collects billions in revenue. American manufacturers who compete with Chinese imports benefit from the price advantage. The fentanyl supply chain — which operates entirely outside legal trade channels — is unaffected. The primary beneficiaries are domestic producers and the administration’s narrative, not American communities affected by fentanyl.

The attribution problem. To the extent that China’s precursor regulations have contributed to declining fentanyl availability (see Item #7), this is primarily the product of Biden-era diplomacy — the November 2023 Biden-Xi summit and the subsequent August 2024 precursor controls. The Trump administration’s contribution — tariff threats — may have provided additional diplomatic pressure, but experts warn this pressure was as likely to undermine cooperation as to enhance it. The causal chain runs through diplomatic agreements and regulatory enforcement, not through tariffs on consumer goods.

Context the Framing Omits

The tariff was struck down by the Supreme Court. Six justices — including three Trump appointees — ruled that IEEPA does not authorize tariffs. The tariff the claim describes no longer exists, having been found to exceed presidential authority. All IEEPA tariffs terminated February 24, 2026.

China exports precursors, not finished fentanyl. The claim says “fentanyl trafficked into our country” but China’s role is as a precursor chemical supplier. Mexican cartels produce the finished fentanyl. U.S. citizens smuggle it through legal ports of entry. The supply chain has three stages, and China’s involvement is at stage one, not stage three.

China’s precursor regulations began under Biden. The diplomatic breakthrough came at the November 2023 Biden-Xi summit. China’s August 2024 controls on key precursor chemicals (4-AP, 1-boc-4-AP, norfentanyl) were the product of this Biden-era engagement. The Trump administration inherited this progress and then risked undermining it with tariffs that Brookings warned would “eviscerate Beijing’s cooperation.”

The tariff was paid by American consumers. Yale Budget Lab found the 10% tariff reduced disposable income by 0.14% on average, with a regressive burden falling hardest on low-income households. The Tax Foundation estimated the combined tariff regime cost approximately $1,500 per household. These are costs to Americans, not to China.

The tariff was raised, reduced, and used as trade leverage. The fentanyl tariff went from 10% to 20% (March 2025) back to 10% (November 2025) based on trade negotiations, not fentanyl metrics. This trajectory reveals the tariff as a trade instrument with a fentanyl label.

Chinese migration is economically driven and tariff-irrelevant. The surge in Chinese border crossings (37,000 in FY2023, up from 330 in FY2021) was driven by economic fallout from China’s zero-COVID policies. A tariff on Chinese imports does not deter individuals from migrating. These are separate phenomena yoked together by the executive order’s language.

Expert consensus: tariffs do not work for this purpose. The Lancet (peer-reviewed), Brookings, WOLA, AEI, STAT News, and former federal commission members all agree tariffs are ineffective against fentanyl. No credible expert assessment supports the claim’s implied theory of change.

Verdict

Factual core: The 10% tariff on Chinese imports was actually imposed. This is true. Executive Order 14195, signed February 4, 2025, did exactly what the claim describes.

The claim is true but the framing is deeply misleading:

1. The tariff’s stated purpose is disconnected from its actual mechanism. A tariff on iPhones, clothing, and toys does not reduce clandestine precursor chemical shipments or unauthorized immigration. The government’s own State Department found China’s precursor enforcement “uneven and opaque” months after the tariff was imposed. Experts across the political spectrum agree tariffs are structurally incapable of affecting illicit drug supply chains.

2. “Fentanyl trafficked into our country” mischaracterizes China’s role. China exports precursor chemicals, not finished fentanyl. Mexican cartels produce the drug. U.S. citizens smuggle it through legal ports of entry. The claim implies direct Chinese fentanyl trafficking that does not exist in the way described.

3. The tariff no longer exists. The Supreme Court ruled 6-3 that IEEPA does not authorize tariffs. All IEEPA tariffs, including this one, terminated February 24, 2026. The administration lists as a “win” a policy that the judiciary found exceeded presidential authority.

4. American consumers paid the cost. The tariff functioned as a tax on American consumers, not a penalty on China. Low-income households bore a disproportionate share. Total IEEPA tariff revenue reached approximately $164.7 billion before the Supreme Court terminated them.

5. The tariff risked undermining the precursor cooperation that was actually working. Biden-era diplomacy produced China’s August 2024 precursor regulations. Brookings warned tariffs would “eviscerate Beijing’s cooperation.” The one anti-fentanyl tool that experts identified as promising — diplomatic precursor regulation — was jeopardized by the very tariff the claim celebrates.

Framing as “win”: The action described is factually true — the tariff was imposed. But listing it as a border security “win” implies it achieved its stated purpose (reducing fentanyl and illegal immigration from China), which no evidence supports and expert consensus contradicts. The tariff was subsequently struck down as exceeding presidential authority. This is a true action presented with a false theory of change in a section where it does not belong.

What a reader should understand: The administration did impose a 10% tariff on all Chinese imports in February 2025, citing fentanyl and illegal immigration — that much is true. But there is no credible evidence or expert consensus that tariffs on consumer goods can reduce illicit drug trafficking or unauthorized immigration. China exports fentanyl precursor chemicals, not finished fentanyl — and the precursor cooperation that was actually reducing fentanyl supply was the product of Biden-era diplomacy that tariffs risked undermining. The tariff was paid by American consumers (an estimated 0.14% income reduction, regressive), was used as trade negotiation leverage (raised to 20%, reduced to 10% based on trade deals, not fentanyl metrics), and was ultimately struck down 6-3 by the Supreme Court as exceeding presidential authority under IEEPA. Experts from Brookings, The Lancet, WOLA, AEI, and STAT News all agree: tariffs are the wrong tool for fentanyl. The claim describes a real action whose stated purpose is contradicted by its mechanism, its trajectory, its expert assessment, and its legal fate.

Cross-References

• Item #7: “Cut fentanyl trafficking at the southern border by 56%” — establishes that fentanyl enters primarily through legal ports of entry (86%) carried by U.S. citizens (81%), and that the fentanyl decline is driven by China’s precursor regulations (Biden-era), Sinaloa cartel civil war, declining purity, and naloxone — not tariffs or border enforcement.
• Item #46: “Forced Canada and Mexico to take meaningful steps to address fentanyl” — the companion claim using tariffs as anti-fentanyl tools. Item #46 documents the same IEEPA tariff framework, the Supreme Court’s invalidation of it, and the expert consensus that tariffs are ineffective against fentanyl. Together, Items #46 and #47 reveal a pattern: tariffs are framed as fentanyl policy but function as trade policy.

Sources

Federal Register. “Executive Order 14195: Imposing Duties To Address the Synthetic Opioid Supply Chain in the People’s Republic of China.” February 7, 2025. https://www.federalregister.gov/documents/2025/02/07/2025-02408/imposing-duties-to-address-the-synthetic-opioid-supply-chain-in-the-peoples-republic-of-china

White House. “Fact Sheet: President Donald J. Trump Imposes Tariffs on Imports from Canada, Mexico and China.” February 1, 2025. https://www.whitehouse.gov/fact-sheets/2025/02/fact-sheet-president-donald-j-trump-imposes-tariffs-on-imports-from-canada-mexico-and-china/

White House. “Modifying Duties Addressing the Synthetic Opioid Supply Chain in the People’s Republic of China.” November 4, 2025. https://www.whitehouse.gov/presidential-actions/2025/11/modifying-duties-addressing-the-synthetic-opioid-supply-chain-in-the-peoples-republic-of-china/

SCOTUSblog. “Supreme Court strikes down tariffs.” February 20, 2026. https://www.scotusblog.com/2026/02/supreme-court-strikes-down-tariffs/

Holland & Knight. “Supreme Court Strikes Down IEEPA Tariffs: What Importers Need to Know Now.” February 2026. https://www.hklaw.com/en/insights/publications/2026/02/supreme-court-strikes-down-ieepa-tariffs

Congressional Research Service. “China Primer: Illicit Fentanyl and China’s Role.” Updated August 2025. https://www.congress.gov/crs-product/IF10890

U.S. Department of State. “Mandatory Congressional Report on China Narcotics.” September 17, 2025. https://www.state.gov/wp-content/uploads/2025/09/Tab-1-Mandatory-Congressional-Report-on-China-Narcotics-Accessible-9.17.2025.pdf

Brookings Institution. “The Fentanyl Crisis: From Naloxone to Tariffs.” Vanda Felbab-Brown. March 2025. https://www.brookings.edu/articles/the-fentanyl-crisis-from-naloxone-to-tariffs/

The Lancet Regional Health — Americas. “Misguided Tariffs Will Not Solve the United States’ Overdose Crisis.” January 2025. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00007-9/fulltext

WOLA. “Tariffs Won’t Stop Fentanyl: Upending U.S.-Mexico Relations for a Failed Drug-War Model.” February 2025. https://www.wola.org/multimedia/tariffs-wont-stop-fentanyl-upending-u-s-mexico-relations-for-a-failed-drug-war-model/

Yale Budget Lab. “Economic and Fiscal Effects of the February 2025 Proposed Tariffs on China.” February 2025. https://budgetlab.yale.edu/research/economic-and-fiscal-effects-february-2025-proposed-tariffs-china

Tax Foundation. “Tariff Tracker: 2026 Trump Tariffs & Trade War by the Numbers.” 2026. https://taxfoundation.org/research/all/federal/trump-tariffs-trade-war/

Penn Wharton Budget Model. “Supreme Court Tariff Ruling: IEEPA Revenue and Potential Refunds.” February 20, 2026. https://budgetmodel.wharton.upenn.edu/issues/2026/2/20/supreme-court-tariff-ruling-ieepa-revenue-and-potential-refunds

NPR. “America’s fentanyl crisis is improving but President Trump used the drug to justify tariffs.” February 2, 2025. https://www.npr.org/2025/02/02/nx-s1-5283957/fentanyl-trump-tariffs-china-canada-mexico

NPR. “Canada and China say the fentanyl crisis is only a ‘pretext’ for Trump’s new tariffs.” March 4, 2025. https://www.npr.org/2025/03/04/nx-s1-5317494/tariffs-fentanyl-canada-mexico-trump

STAT News. “Tariffs can’t defeat the fentanyl problem in the US.” Kathleen J. Frydl. July 3, 2025. https://www.statnews.com/2025/07/03/fentanyl-border-adjustments-tariffs-mexico-china-policy/

Brookings Institution. “US-China Relations and Fentanyl and Precursor Cooperation in 2024.” 2024. https://www.brookings.edu/articles/us-china-relations-and-fentanyl-and-precursor-cooperation-in-2024/

Holland & Knight. “China’s Comprehensive Retaliation Against U.S. Tariffs.” April 2025. https://www.hklaw.com/en/insights/publications/2025/04/chinas-comprehensive-retaliation-against-us-tariffs